Differences in Biomarkers in Patients With Heart Failure With a Reduced vs a Preserved Left Ventricular Ejection Fraction
Simon de Denus(Montreal Heart Institute), Michel White(Montreal Heart Institute), Normand Racine(Montreal Heart Institute), Paul‐Eduard Neagoe(Montreal Heart Institute), Martin G. Sirois(Montreal Heart Institute), Li Zhu(Jiangsu University), Jean‐Lucien Rouleau(Montreal Heart Institute), Anique Ducharme(Montreal Heart Institute), Joël Lavoie(Montreal Heart Institute), Eileen O’Meara(Montreal Heart Institute)
Cited by 29
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
|New England Journal of Medicine|2004|1.9k
Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure
|New England Journal of Medicine|2008|1.6k